The ITAC trial will establish if hyperimmune intravenous immunoglobulin (hIVIG) plus remdesivir can improve COVID-19 patient outcomes.
Grant Courtney explains why traceability is vital as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed.